Biointron

09/03/2026

🎉 𝗥𝘂𝘀𝗵𝗗𝗮𝘁𝗮 𝗟𝗮𝘂𝗻𝗰𝗵 𝗣𝗿𝗶𝗰𝗶𝗻𝗴: 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗖𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗮𝘁 𝗙𝘂𝗹𝗹 𝗦𝗽𝗲𝗲𝗱

To celebrate the launch of RushData, we’re giving new customers more opportunities to generate the antibody data they need for their next discovery cycle!

With our RushData Assay Discount Bundle, you can save while evaluating more antibody candidates:

🧪 Order 1 × 96-well plate → Get 50% OFF
🧪 Order 2+ × 96-well plates → Get your 1st plate FREE

RushData brings together gene synthesis, 1-day CHO expression, and high-throughput antibody characterization in one integrated workflow—helping turn antibody sequences into structured experimental data in days.

📅 Offer valid September 1 - December 31, 2026 for new customers

👉 Learn more & apply for the offer: https://www.biointron.com/promotions/rushdata-launch.html?utm_source=linkedin&utm_medium=post&utm_campaign=rushdata_2026

Get 50% off or a free plate with Biointron's RushData launch offer. 1-day CHO expression, high-throughput antibody characterization. Offer ends 12/31/26.

09/03/2026

𝐖𝐞 𝐚𝐫𝐞 𝐞𝐱𝐜𝐢𝐭𝐞𝐝 𝐭𝐨 𝐚𝐭𝐭𝐞𝐧𝐝 𝐭𝐡𝐞 𝐀𝐑𝐃𝐃 𝟐𝟎𝟐𝟔 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 𝐧𝐞𝐱𝐭 𝐦𝐨𝐧𝐭𝐡!

Join us for a conversation on advances in antibody research for aging therapies!

📅 Date: October 1 - 3, 2026
📍 Location: David Rubenstein Treehouse | Boston, MA
🔬 Booth #10

Register for a 1-on-1 time with us here:
🔗https://www.surveymonkey.com/r/J2NHKBB

09/02/2026

𝐓𝐡𝐞 𝐖𝐨𝐫𝐥𝐝 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐒𝐮𝐦𝐦𝐢𝐭 𝐢𝐧 𝐁𝐨𝐬𝐭𝐨𝐧 𝐢𝐬 𝐎𝐧𝐥𝐲 𝟐 𝐖𝐞𝐞𝐤𝐬 𝐀𝐰𝐚𝐲!

Join us for a conversation on advances in bispecific antibody development. We look forward to connecting with you in Boston again!

📅 Date: September 15 - 17, 2026
📍 Location: The Westin Boston Seaport | Boston, MA
🔬 Booth #6

Register for a 1-on-1 time with us here:
🔗https://www.surveymonkey.com/r/GLCH8XF

Take this survey powered by surveymonkey.com. Create your own surveys for free.

08/31/2026

👏 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗥𝗲𝗴𝗲𝗻𝗲𝗿𝗼𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗼𝗳 𝗣𝗮𝘀𝗮𝘁𝗿𝘂 (𝗴𝗮𝗿𝗲𝘁𝗼𝘀𝗺𝗮𝗯-𝗴𝗿𝘁𝘀) 𝗯𝘆 𝘁𝗵𝗲 𝗙𝗗𝗔!

Structure/Target(s): Fully human IgG4 monoclonal antibody targeting Activin A
Indication: Fibrodysplasia ossificans progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability.

Garetosmab binds to and neutralizes Activin A, which is an obligate driver of heterotopic ossification in FOP. Garetosmab thus reduces formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with FOP.

Read the press release here 👉 https://investor.regeneron.com/news-releases/news-release-details/pasatrutm-garetosmab-grts-first-and-only-fda-approved-treatment

08/26/2026

🚀 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗼𝗻 Scientist.com: 𝗪𝗵𝗮𝘁 𝗘𝘅𝗽𝗲𝗿𝗶𝗺𝗲𝗻𝘁𝗮𝗹 𝗗𝗮𝘁𝗮 𝗗𝗼 𝗔𝗜-𝗗𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗡𝗲𝗲𝗱?

Artificial intelligence is expanding what researchers can do computationally in antibody discovery. Models can generate antibody sequences, predict three-dimensional structures, identify potential binding interfaces, and estimate properties relevant to affinity and developability. In some cases, these approaches allow large numbers of candidate designs to be prioritized computationally before experimental work begins.

Yet a designed sequence remains a hypothesis about a molecule.

Read it here 👉 https://www.scientist.com/blog/what-experimental-data-do-ai-designed-antibodies-need

This blog was written by Biointron, a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. From gene sequence to purified antibodies, production only takes 2 weeks — and with RushData, an AI antibody wet lab validation service, com...

08/24/2026

🌟 𝗢𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗱𝗲𝗹𝘃𝗲𝘀 𝗶𝗻𝘁𝗼 𝘄𝗵𝗲𝗿𝗲 𝘁𝗵𝗲 𝗲𝘅𝗽𝗲𝗿𝗶𝗺𝗲𝗻𝘁𝗮𝗹 𝗱𝗮𝘁𝗮 𝗳𝗼𝗿 𝗔𝗜-𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗰𝗼𝗺𝗲 𝗳𝗿𝗼𝗺 💡

At Biointron, we specialize in antibody production and discovery – dedicating ourselves to advancing human health and promoting sustainability with more than 14 years of experience and over 3,000 customers globally. We offer premium solutions at competitive rates, all anchored in our commitment to a brighter and healthier future.

Read the original here: https://www.biointron.com/blog/ai-can-design-antibodies-with-experimental-data.html

Artificial intelligence is quickly becoming part of monoclonal antibody discovery. Models can now help generate antibody sequences, predict three-dimensional structures, identify likely binding sites, estimate antibody-antigen interactions, and flag developability risks before a candidate reaches th...

08/14/2026

🤖 𝗛𝗼𝘄 𝗶𝘀 𝗔𝗜 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗺𝗼𝗻𝗼𝗰𝗹𝗼𝗻𝗮𝗹 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁?

We know that artificial intelligence is increasingly being integrated into monoclonal antibody discovery and optimization – here’s what they are helping on:

• Sequence design (generating and evaluating antibody sequences with desired properties)

• Epitope-paratope prediction (identifying how antibodies may interact with their targets)

• Affinity optimization (predicting sequence changes that could improve binding)

• Structural prediction (modeling antibody structure and antibody–antigen interactions)

• Developability assessment (identifying potential risks such as aggregation or poor stability earlier in the development process)

Traditional antibody development relies heavily on experimental screening and optimization. While AI does not replace experimental validation, the most effective approach combines computational prediction and design with high-throughput experimental testing, creating a feedback loop between in silico models and real-world antibody data.

Read the paper here 👉 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1802038/full

Biointron's RushData supports AI drug discovery companies with the experimental validation needed: https://www.biointron.com/antibody-production/rushdata.html

Monoclonal antibody–based therapeutics have become essential tools for treating infectious, autoimmune, and malignant diseases due to their high specificity ...

08/13/2026

𝗔 𝗻𝗲𝘄 𝗹𝗶𝗻𝗸𝗲𝗿 𝗯𝗿𝗼𝗮𝗱𝗲𝗻𝘀 𝘁𝗵𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝘄𝗶𝗻𝗱𝗼𝘄 𝗼𝗳 𝗮𝘂𝗿𝗶𝘀𝘁𝗮𝘁𝗶𝗻-𝗯𝗮𝘀𝗲𝗱 𝗔𝗗𝗖𝘀!

A recent study reported a novel DLeu-Ala-Glu tripeptide linker for MMAE-based ADCs designed to reduce off-target drug release in bone marrow.

Compared with the commonly used Val-Cit linke, the new linker was less susceptible to neutrophil proteases while maintaining intracellular payload release and antitumor activity.

In animal models, ADCs using this linker showed:
• Reduced bone marrow toxicity
• Improved tolerability at higher doses
• Preserved antitumor efficacy

The study suggests that optimizing both protease selectivity and linker hydrophilicity could help improve the therapeutic index of MMAE-based ADCs.

Read the paper here: https://pubs.acs.org/bcches/article/doi/10.1021/acs.bioconjchem.6c00234/5210672/Discovery-of-a-Novel-Tripeptide-Linker-that

Abstract. Vedotin-based antibody–drug conjugates (ADCs) employing the valine–citrulline (Val–Cit) dipeptide linker and monomethyl auristatin E (MMAE) have

08/11/2026

Roundup of deals in July 2026 👇

🤝 argenxglobal to acquire Forte Biosciences in $2.2B deal, adding anti-CD122 antibody, FB102, to pipeline. FB102 has clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune disease. https://argenx.com/news/2026/press-release-3333257

🤝 Novartis to acquire Myricx Bio, adding N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads in up to $1.5B deal. https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients

💵 Spero Therapeutics pivots to I&I with $1.1B licensing deal for Innovent Biologics' IBI355 (an anti-CD40L mAb). They plan to initiate a Phase 2 trial for IBI355 in Q2 2027 in IgG4-related disease. https://www.sperotx.com/investors/press-release/?i=168118

🤝 Ipsen to acquire Memo Therapeutics AG, adding potravitug, a BK polyomavirus monoclonal antibody, expanding rare disease portfolio, in €700M ($796M) deal. https://www.ipsen.com/press-release/ipsen-to-acquire-memo-therapeutics-ag-adding-first-in-class-bk-polyomavirus-antibody-expanding-rare-disease-portfolio-3320317/

🤝 Chemomab Therapeutics and Scipher Medicine to merge, advancing nebokitug (an anti-CCL24 mAb) in an AI-powered phase 2 trial in rheumatoid arthritis. https://www.sciphermedicine.com/chemomab-therapeutics-and-precision-medicine-pioneer-scipher-medicine-announce/

🤖 Chai Discovery to collaborate with both Novartis and argenx to advance AI-driven antibody discovery for therapeutic programs across multiple targets. https://www.businesswire.com/news/home/20260702507776/en/Chai-Discovery-Announces-Collaboration-with-Novartis-to-Advance-AI-Driven-Antibody-Discovery

🤖 Chai Discovery also announces $400M Series C to advance AI-driven molecular design, thus valuing the company at $3.8B. Their models aim to predict and reprogram the interactions between molecules. https://www.businesswire.com/news/home/20260713849009/en/Chai-Discovery-Announces-%24400M-Series-C-to-Advance-AI-Driven-Molecular-Design

💸 Trellis Bioscience closes $9M Series C financing to support Phase 2 trial of calpurbatug (TRL1068), an investigational mAb treatment for chronic prosthetic joint infections (PJI). https://www.prnewswire.com/news-releases/trellis-bioscience-raises-9-million-to-advance-clinical-development-of-calpurbatug-trl1068-302828030.html

🤝 Jasper Therapeutics to merge with Kira Pharmaceuticals, advancing pipeline of therapies for immunologically-driven disorders, including briquilimab, an anti-KIT antibody, and KP-701, an anti-CD79BxCD32B mAb. https://ir.jaspertherapeutics.com/news-releases/news-release-details/jasper-therapeutics-announces-merger-kira-pharmaceuticals

💵 Mirador Therapeutics expands precision immunology portfolio with exclusive license to Kira Pharmaceuticals’ KP-301, a long-acting anti-C5a antibody. https://www.miradortx.com/news/mirador-therapeutics-expands-precision-immunology-portfolio-exclusive-license-kp-301-long

🔬 Akari Therapeutics enters strategic research collaboration with Whitehawk Therapeutics, combining PH1 spliceosome-modulating payload technology with a TOP1i ADC platform. https://akaritx.com/2026/07/21/akari-therapeutics-enters-strategic-research-collaboration-with-whitehawk-therapeutics/

🤝 Synlogic and Caldera Therapeutics announce merger agreement and concurrent $278M private placement. They will develop CLD-423, a TL1A x IL-23p19 bispecific for inflammatory bowel disease and other immune-mediated diseases.https://calderatx.com/wp-content/uploads/2026/07/press-release-07292026-synlogic-and-caldera-therapeutics-announce-merger-agreement-and-concurrent-private-placement.pdf

🔬 AbCellera to collaborate with Vertex to discover multispecific T-cell engagers for autoimmune diseases and other conditions. https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-Collaboration-with-Vertex-to-Discover-Multispecific-T-Cell-Engagers-for-Autoimmune-Diseases-and-Other-Conditions/default.aspx

🔬 Kairos Pharma Ltd. announces strategic collaboration with Bayer to evaluate antibody ENV-105 (carotuximab) in combination with XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. https://investors.kairospharma.com/news-and-events/news-releases/news-details/2026/Kairos-Pharma-Announces-Strategic-Collaboration-with-Bayer-to-Enhance-XOFIGO-Activity-in-Metastatic-Prostate-Cancer/default.aspx

08/07/2026

🎉 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗼𝘂𝗿 𝗤𝟯 𝟮𝟬𝟮𝟲 𝗧𝗿𝗮𝘃𝗲𝗹 𝗚𝗿𝗮𝗻𝘁 𝗪𝗶𝗻𝗻𝗲𝗿!

We are excited to announce that Federico Uggeri, a PhD student at Università degli Studi di Milano, has been selected as Biointron’s Q3 2026 Travel Grant recipient!

📍 Uggeri will be attending the 17th World ADC San Diego (October 12–15, 2026). Biointron will also be exhibiting, so be sure to check out our booth!

Federico Uggeri graduated in Chemistry cm laude at Università degli Studi di Milano in 2024, with a Master's thesis in the synthesis of salicylaldehyde-tagged peptides. He is currently pursuing his doctoral studies in Chemistry at the same institution, under the supervision of Prof. Alberto Dal Corso, with a scholarship co-funded by Takis srl (Rome, IT). His research focuses on the design and synthesis of antibody–drug conjugates (ADCs), with particular interest in the development of novel self-immolative spacers for controlled payload release. His work aims to improve the selectivity and therapeutic potential of targeted cancer therapies.

👉 Interested in attending a conference with support from Biointron? Apply for our travel grant program here: https://www.biointron.com/promotions/travel-grant-program.html